Last updated: July 5, 2026
CRINONE (crinone) Investment Scenario and Fundamentals Analysis: Patents, Exclusivity, Generics Risk, and Commercial Outlook
CRINONE is a branded progesterone gel product (endometrial support in assisted reproduction) marketed in the US and other markets as a local intravaginal therapy. From an investment perspective, the key question is not next-generation IP, but how long branded exclusivity and formulation/method IP can delay generic entry, and whether payer mix plus persistent indication demand sustain pricing power.
Bottom line: CRINONE’s investment attractiveness is driven by (1) US patent and exclusivity timelines, (2) strength and enforceability of Orange Book-listed IP around formulation and use, (3) generic entry probability via ANDA/Biowaiver feasibility for intravaginal gels, and (4) volume sensitivity and reimbursement dynamics for fertility and women’s health indications.
What is CRINONE and what products compete with it?
CRINONE is an intravaginal progesterone formulation used primarily for luteal phase support and endometrial preparation in assisted reproductive technologies (ART), with use patterns often tied to IVF cycles. In many markets, intravaginal progesterone gels or suppositories and oral progesterone compete on cost, convenience, and formulary access.
Competitive set and substitute classes
- Other intravaginal progesterone gels (same route, same hormone target)
- Vaginal progesterone suppositories/capsules (different product design, similar active)
- Vaginal or oral progestins used for similar reproductive indications (market-dependent)
- Injectable progesterone (lower convenience, but can win on payer economics in some settings)
Investment relevance: Route of administration and ease-of-use influence adherence and payer approvals. If payer formularies favor lower-cost vaginal products, CRINONE’s margin resilience is structurally constrained even without generic competition.
What patents protect CRINONE in the US and which claims matter for a generic?
For patent-landscape work, the critical unit is whether CRINONE’s Orange Book–listed patents include:
- Composition/formulation claims (polymer, mucoadhesive base, viscosity modifiers)
- Method-of-use claims tied to ART dosing or regimen
- Manufacturing process claims affecting feasibility of “generic equivalence”
Featured snippet answer: For intravaginal progesterone products, generic entry typically hinges on whether Orange Book patents cover the formulation and whether method-of-use claims restrict label carving beyond basic progesterone activity.
What to look for in the patent estate
- Listed patents tied to the drug product (NDA), not only “related” progesterone compounds
- Expiration dates and terminal disclaimers affecting enforceable term
- Continuation practice (RCE, CIP) that may extend pendency and listing timing
- Claim scope that covers gel base composition or defined ranges of rheology/viscosity
Investment relevance: A strong formulation patent with broad claim coverage can force generics into design-arounds that affect bioequivalence and labeling, reducing immediate substitution speed.
When does CRINONE lose exclusivity in the US?
Exclusivity usually comes in two layers:
- Regulatory exclusivity (NCE, new clinical studies, or pediatric exclusivity, as applicable)
- Patent exclusivity via Orange Book listing and listed-patent expiration
Featured snippet answer: The latest effective exclusivity date is the maximum of the last expiring listed patent and any granted regulatory exclusivity for the NDA.
Timing-driven entry risk
- If the last listed patent is near term, the generic pipeline may be “hard-wired” to launch at the patent cliff.
- If patents are staggered by formulation and use, entry may come in phases (partial label first, then broader substitution later).
Investment relevance: For an investment thesis, the question is less “when does a single patent expire” and more “what is the first day a generic can safely ship with the label/patient-use expectations CRINONE holds.”
What is the Orange Book status of CRINONE and what patents are listed?
The Orange Book is the practical gatekeeper for ANDA timelines because it governs:
- Whether applicants must certify to each listed patent (Paragraph I, II, III, IV)
- Whether a Paragraph IV filing triggers an automatic 30-month stay (where applicable)
Featured snippet answer: The Orange Book status determines how and when generics can challenge patents and when they can launch.
Orange Book–driven investment indicators
- Number of listed patents (more listings usually means a longer negotiation and litigation runway)
- Patent classes (formulation vs method-of-use)
- Whether key patents are expiring early or late
- History of Paragraph IV certifications (signals generic willingness to litigate)
Investment relevance: Even when expiration is close, multiple listed patents can prevent an “easy” first-to-file launch that fully substitutes CRINONE’s labeled positioning.
How strong is the patent estate for CRINONE (formulation, method-of-use, and process)?
Patent “strength” for investment purposes is about:
- Breadth of independent claims
- Evidence of enforceability (survived reexams/IV litigation)
- Likelihood of successful design-around
Formulation patents
- For intravaginal gels, formulation patents can be hard to design around because viscosity, mucoadhesion, and stability are tied to the base composition and excipients.
Method-of-use patents
- Method-of-use claims are vulnerable to label carve-outs and at-times more dependent on US practice patterns.
- If the CRINONE label is carved narrowly, method-of-use enforcement can weaken, enabling generics to launch with a different regimen if legally allowed.
Process/manufacturing patents
- Often provide secondary barriers but rarely provide the dominant blocker unless they are specifically required for release specs.
Investment relevance: A portfolio dominated by broad formulation claims tends to reduce near-term generic substitution speed. A portfolio dominated by narrow method-of-use claims tends to allow faster label competition once a generic can certify to non-infringement for remaining claims.
What generic entry risks exist for CRINONE and how many ANDAs/Paragraph IV challenges are there?
Generic entry risk is defined by the interaction of:
- Patent cliff timing
- ANDA filing and Paragraph IV strategy
- Litigation outcomes and settlements
- Practical bioequivalence feasibility for intravaginal products
Key risk paths
- Early generic filing with a Paragraph IV: raises the probability of litigation and delayed launch but increases the likelihood of eventual entry.
- Non-Paragraph IV entry once patents expire or are cleared: increases the probability of rapid substitution.
- Design-around strategy: slower if formulation is tightly protected.
Investment relevance: The highest risk period is the six-to-twelve months preceding the first “launch date” created by the last blocking patent expiration or settlement.
What CRINONE patent litigation affects investors and what settlement patterns matter?
For investors, litigation matters because it can:
- Define the launch date via settlement
- Limit the generic’s labeled indication
- Create “at-risk” periods where uncertainty persists but launch is possible
What to map in litigation
- Parties (NDA holder vs Paragraph IV filer)
- Assered patent(s) and claim construction issues
- Injunction posture or consent judgments
- Settlement terms that include:
- Date of entry
- Label carve-outs
- Royalty or consideration
- “No launch” covenants
Investment relevance: Settlements can shift exclusivity by months to years beyond the nominal patent expiration timeline depending on negotiated terms.
What biosimilar risk exists for CRINONE?
CRINONE is a small-molecule progesterone product, not a biologic. The biosimilar framework does not apply.
Featured snippet answer: Biosimilar risk is not a factor; the competitive threat is generic (ANDA) substitution, not a biologics pathway.
What formulations are protected for CRINONE and do they cover all strengths?
For intravaginal hormone products, IP coverage often varies by:
- Strength (mg content)
- Packaging (applicator design)
- Gel base composition and release characteristics
Investment relevance: If only certain strengths are protected, generics may launch for unprotected strengths first, fragmenting the revenue pool.
Dosage forms to track
- Intravaginal gel presentation
- Applicator type
- Strength and dosing regimen in the label
How does CRINONE compare with alternative progesterone products on commercial fundamentals?
Commercial strength depends on:
- Formulary access and step edits
- Wholesale acquisition cost trends versus generics
- Patient adherence and physician preference
- Indication-specific demand (ART volumes and clinics’ prescribing patterns)
Pricing and volume dynamics
- Branded progesterone products typically face pricing pressure after generic entry.
- Basket substitution can happen quickly if payers classify alternatives as therapeutically equivalent.
Investment relevance: Post-generic substitution, revenue retention is often determined by market share resiliency and whether any remaining patents delay full interchangeability.
Revenue exposure: what portion of CRINONE depends on patent-protected substitution timing?
Revenue exposure is usually concentrated in:
- The US market (highest generic filing density)
- Indication-driven prescribing that is stable across IVF clinics
Featured snippet answer: The core revenue risk is the first date when a generic can launch with label-positioning that enables payer substitution.
Investment indicator set
- Time to patent expiry
- Litigation and settlement calendar
- ANDA readiness signals (amended labels, manufacturing approvals)
- Evidence of formulary switching behavior historically in similar progesterone categories
Which regulatory milestones at FDA shape CRINONE’s exclusivity and generic timelines?
For the brand, FDA milestones relevant to exclusivity include:
- NDA approval date
- Any supplements that generate new exclusivity periods (if applicable)
- Orange Book patent listing updates
For generics, the operational milestones include:
- ANDA submission
- FDA acceptance and approval
- Bioequivalence study acceptance for intravaginal delivery
- Label finalization
Investment relevance: “Regulatory slack” can either delay or accelerate generic approval once patents are cleared.
What is the likely US generic launch scenario for CRINONE if patents expire?
A realistic launch scenario depends on:
- Whether a generic has an approved ANDA ready at approval time
- Whether it has settled or cleared blocking patents
- Whether it can obtain “drop-in” labeling that supports substitution
Scenario map
- Blocking patent expires first: generic approval may follow quickly, but launch can be delayed by litigation or launch-year contracting.
- Settlement sets a later date: brand may retain market share longer than the patent expiration suggests.
- Label carve-out: generic launches but brand keeps share in patient subsets where the protected regimen applies.
Investment relevance: Investors should model revenue assuming substitution is not only a legal event but a payer-contracting and clinic-adoption event.
Which companies are challenging CRINONE and what does that imply for timing?
Paragraph IV filers often choose challengers with manufacturing readiness and litigation leverage.
Investment relevance: A known challenger with prior success in ANDA litigations often increases the probability of a timely launch at the end of a 30-month stay or settlement date.
(No company-specific entities are listed here because an accurate mapping requires the current Orange Book entry set and litigation docket identification for CRINONE. This write-up does not provide unverified names.)
What is the geographic scope of CRINONE exclusivity and competitive risk?
Exclusivity and generic timing typically vary by jurisdiction:
- US: ORANGE BOOK drives ANDA certification and litigation stays
- EU: national patent enforcement and marketing authorization rules
- UK: UK SPC and patent enforcement if applicable
- Emerging markets: enforcement risk is often lower, increasing early supply substitution
Investment relevance: Even when US exclusivity persists, other markets may erode brand value and reduce overall revenue stability.
Key Takeaways
- CRINONE’s investment thesis is primarily driven by US Orange Book–listed patents and the enforceable exclusivity calendar, not biosimilar risk.
- The largest revenue risk is the first day a generic can launch with label-positioning that supports payer substitution.
- Formulation and method-of-use claim scope determine whether generics can enter quickly or require design-around that slows substitution.
- Litigation and settlement can shift entry dates materially beyond simple patent expiration.
- Commercial fundamentals hinge on payer formulary behavior and clinic adoption, which often accelerate after generic availability.
FAQs
1) How does Orange Book patent certification (Paragraph IV) affect CRINONE generic launch dates?
Certification drives litigation timing and can trigger statutory stays, delaying approval and/or launch.
2) Does CRINONE face biosimilar competition?
No. CRINONE is a small-molecule progesterone product, so the relevant threat is generic substitution via ANDA.
3) What matters more for CRINONE’s IP: formulation, method-of-use, or manufacturing process?
For intravaginal gels, formulation claims usually present the most practical barrier; method-of-use can be circumvented through label carve-outs depending on claim scope.
4) What determines whether CRINONE loses share after patent expiry?
Payer interchangeability decisions, contract pricing, and how quickly clinics switch once a generic is launched with an adequate label.
5) What investor metrics best track near-term CRINONE exclusivity cliff risk?
Time to last blocking Orange Book patent expiration, history of Paragraph IV filings, litigation docket milestones, and settlement/consent calendar that sets practical entry dates.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Patent and Trademark Office. (n.d.). Patent Application Information and Patent Claims. https://www.uspto.gov/
- Hatch-Waxman Act, 21 U.S.C. § 355 (j). (n.d.). Drug approval pathway and exclusivity framework. https://uscode.house.gov/
